Author Archives: admin

Musk Announces X Will Open-Source All Algorithms Within 7 Days, Including Recommendation Engine; Updates to Follow Every Four Weeks

Elon Musk has recently pledged to open-source the platform’s new algorithms to the public within the next seven days, marking a radical step forward in transparency for the social media giant.

In a post on X this Saturday, Musk stated that this open-source initiative is not a one-time event but will become a regular mechanism. He noted that X will repeat the algorithm disclosure process every four weeks, accompanied by detailed developer notes designed to help external parties clearly understand specific changes.

The announcement comes at a time of mounting friction between X and global regulators over content moderation and recommendation mechanisms. By regularly disclosing its algorithms, X may be attempting to alleviate external concerns regarding its opaque operations while addressing user criticism over the quality of feed recommendations. However, Musk did not explicitly state the specific motivation behind this sudden decision to open-source.

This move could have profound implications for the digital advertising market and social media operating models. If the core recommendation logic becomes fully transparent, it will not only shift strategies for content creators but also allow advertisers to more intuitively understand how their content reaches audiences. Simultaneously, it provides regulators with direct evidence to scrutinize the platform for potential bias or manipulation.

Transition to AI-Driven Recommendation

X is currently focused on deepening the application of artificial intelligence within its recommendation algorithms. Last October, Musk stated that improvements in user feeds resulted not from manual adjustments to heuristic rules, but from an increased reliance on Grok and other AI tools.

According to Musk’s previous disclosures, the company aims to make X’s recommendation engine “purely AI-driven.” The plan involves utilizing Grok, Musk’s AI chatbot, to evaluate the more than 100 million posts published on X daily. After being filtered by Grok, the system pushes content most likely to interest individual users. Musk has asserted that this mechanism will “profoundly improve the quality of the feed.”

In September of last year, Musk proposed an even more frequent open-source schedule, claiming the platform would share its algorithms every two weeks. Although the frequency has been adjusted to every four weeks, it still indicates the company’s intent to fully integrate AI into its core operational architecture.

While Musk has made multiple promises to open parts of X’s algorithm in recent years, actual execution has been inconsistent. Prior to this announcement, some X users complained about seeing fewer posts from people they follow due to platform changes.

Addressing this issue last October, Musk confirmed that the company had discovered a “major bug” in the “For You” algorithm and promised a fix. The announcement of full open-sourcing and periodic updates may be a further step toward repairing trust and technical vulnerabilities.

Intensifying Global Regulatory Pressure

Musk’s announcement comes as X faces increasingly stringent scrutiny from global regulators, primarily focused on the spread of misinformation, inadequate content moderation, and a lack of transparency.

European regulators, in particular, have stepped up their focus. In an investigation last July, France requested that X share its algorithms to investigate allegations of bias and manipulation. At the time, X refused the request, dismissing the investigation as politically motivated.

Furthermore, Grok’s image generation feature has recently come under fire for producing a large volume of sexualized AI-generated images of women and children. UK Prime Minister Keir Starmer has demanded “urgent rectification” from X this week, while UK Technology Secretary Liz Kendall warned that access to the service could be blocked in the UK if it fails to comply with the law. Indonesia has already blocked Grok over concerns regarding the generation of sexual content. As of Friday, Grok informed X users that image generation and editing features will transition to a paid subscription service, removing the initial free allowance.

Brent Crude Surges 5% to Two-Week High Amid Venezuela Unrest and Supply Concerns

International oil prices rebounded on Thursday after two consecutive days of declines, with Brent crude jumping as much as 5% to hit a two-week high.

Despite U.S. plans to sell up to 50 million barrels of Venezuelan crude to domestic refiners and a rise in U.S. gasoline and distillate inventories, oil prices were driven higher by investor assessments of the developing situation in Venezuela and mounting concerns over supply disruptions in Russia, Iraq, and Iran.

On Wednesday, U.S. Energy Secretary Chris Wright stated in a media interview that Chevron is expected to rapidly expand its operations in Venezuela, with ConocoPhillips and ExxonMobil also seeking constructive roles. However, energy consultancy Ritterbusch and Associates noted:

“It could take years for significant volumes of Venezuelan crude to reach the U.S. Gulf Coast region.”

The market is simultaneously monitoring supply risks from other major producers. Reports emerged of a drone attack on a tanker bound for Russia in the Black Sea. Meanwhile, Iraq is moving forward with the nationalization of the West Qurna 2 oil field following U.S. sanctions on Russia’s Lukoil. In Iran, nationwide protests fueled by economic hardship have led to a widespread internet shutdown.

Closing Prices

On Thursday, Brent crude futures settled up $2.03, or 3.4%, at $61.99 per barrel, marking its highest close since December 24 of last year. WTI crude futures rose $1.77, or 3.2%, to settle at $57.76 per barrel.

Eli Lilly’s “Weight-Loss Wonder Drug” Combination Shows Remarkable Efficacy, Accelerating Expansion into Immunology

A latest study from Eli Lilly (LLY) reveals that combining its popular weight-loss injection, Zepbound, with the arthritis drug Taltz, is significantly more effective at relieving joint pain and swelling than using either drug alone. This Lilly-backed research opens a new frontier for the application of GLP-1 medications in inflammatory and autoimmune diseases.

Key Study Findings

The study enrolled 271 patients suffering from both obesity and active psoriatic arthritis. Results showed that the combination therapy outperformed Taltz monotherapy in helping patients lose weight and manage arthritis symptoms, meeting the trial’s primary objectives. According to a statement from Eli Lilly, approximately one-third of patients on the combination therapy saw their psoriatic arthritis symptoms reduced by at least half, compared to 20.4% of those using only Taltz.

GLP-1 receptor agonists like Zepbound have already been proven to lower inflammation levels in patients with diabetes and obesity. While observational studies and case reports have previously linked them to improvements in autoimmune conditions such as psoriasis, this study provides the first clinical validation of that theory.

Broadening the Scope of Treatment

With the obesity drug market projected to reach $100 billion by 2030, part of Zepbound’s appeal lies in its potential to address other health complications, including sleep apnea and heart failure. Eli Lilly has integrated this cross-disciplinary approach into the development of its next-generation weight-loss drug, retatrutide, which is currently being studied for conditions such as knee osteoarthritis and chronic kidney disease.

Eli Lilly stated it plans to discuss the study results with regulatory agencies, a move that could lead to expanded label indications or modified clinical treatment recommendations. In the United States, approximately 65% of adults with psoriatic arthritis are also obese, meaning the majority of these patients already qualify for Zepbound treatment.

Strategic Growth and Acquisitions

The Indianapolis-based pharmaceutical giant is also exploring the efficacy of the Zepbound-Taltz combination for plaque psoriasis and inflammatory bowel disease. Results for the plaque psoriasis trial are expected to be released in the first half of this year.

Taltz is one of several Eli Lilly drugs treating inflammatory conditions, with annual sales exceeding $3 billion; however, its key patent protections are set to expire in the coming years. This combination research is a core component of Lilly’s strategy to leverage its success in obesity to drive growth in other sectors like immunology.

Furthermore, the company is actively pursuing deals to bolster its pipeline. On Wednesday, Eli Lilly announced it would acquire Ventyx Biosciences ($VTYX.US) for up to $1.2 billion, gaining access to oral therapies for inflammatory diseases. This acquisition builds on earlier deals for companies like Morphic Therapeutic and Dice Therapeutics, which specialize in oral autoimmune treatments.